|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Division of Translational Research and 3Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto; and 2Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Submitted 3 June 2006 ; accepted in final form 9 January 2007
One of the major manifestations of obesity is an increased production of the adipocyte-derived 16-kDa peptide leptin, which acts mainly on hypothalamic leptin receptors. Leptin receptors are widely distributed in various tissues, including the heart. Whereas increased plasma leptin levels have been reported in patients with congestive heart failure, systemic alterations induced by obesity can affect cardiac hypertrophy, and the direct effects of leptin on cardiac structure and function still remain to be determined. We first exposed primary cardiac myocytes from neonatal rats to leptin for 48 h. This resulted in a significant increase in myocyte long-axis length (P < 0.05 at 50 ng/ml) but not in the short-axis width. Leptin induced the rapid phosphorylation of STAT3 and its DNA binding in cardiac myocytes. Administration of a JAK2 inhibitor, AG-490, completely inhibited all of these effects by leptin. Furthermore, we examined the effect of continuous infusion of leptin for 4 wk following myocardial infarction in mice. Echocardiography demonstrated that left ventricular fractional shortening in the leptin-infused group (28.4 ± 2.8%) was significantly higher than that in the PBS-infused group (18.4 ± 2.2%) following myocardial infarction. Interestingly, left ventricular diastolic dimension in the leptin-infused group (4.56 ± 0.12 mm) was also higher than that in the PBS-infused group (4.13 ± 0.09 mm). These results demonstrate that leptin induces the elongation of cardiac myocytes via a JAK/STAT pathway and chronic leptin infusion causes eccentric dilatation with augmented systolic function after myocardial infarction.
obesity; hypertrophy; heart failure; signal transduction
This article has been cited by other articles:
![]() |
M. Kurdi and G. W. Booz JAK redux: a second look at the regulation and role of JAKs in the heart Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1545 - H1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Roberts, A. L. Clark, and K. K. Witte Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease -- do we need to screen our patients? Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 153 - 163. [Abstract] [PDF] |
||||
![]() |
T. Horie, K. Ono, M. Kinoshita, H. Nishi, K. Nagao, T. Kawamura, Y. Abe, H. Wada, A. Shimatsu, T. Kita, et al. TG-interacting factor is required for the differentiation of preadipocytes J. Lipid Res., June 1, 2008; 49(6): 1224 - 1234. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Pemberton Leptin-induced cardiac hypertrophy: RhoAing a lipid raft down a protective p38 MAPK signalling stream? Cardiovasc Res, January 1, 2008; 77(1): 4 - 5. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |